Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (41-50 of 666) with videos related to

Pageof 67
Sort By:
BMJ (Clinical Research Ed.)|October 1, 1994
Protection afforded by cycle helmetsF McDermott, J Lane
Virchows Archiv. B, Cell Pathology|August 25, 1978
Epithelial cell population kinetics of isolated ileal loops (thirty-vella fistulae) after 40% small in testinal resection. Autoradiographic studies in the ratF McDermott, B Roudnew
The Medical Journal of Australia|December 30, 1978
Compulsory blood alcohol testing of road crash casualties in Victoria: the first three yearsF McDermott, P Strang
Current Opinion in Rheumatology|December 2, 2016
Lessons from characterization and treatment of the autoinflammatory syndromesIvona Aksentijevich, Michael F McDermott
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2003
BMS-561392. Bristol-Myers SquibbMartin Grootveld, Michael F McDermott
Plos Medicine|September 1, 2006
A proposed classification of the immunological diseasesDennis McGonagle, Michael F McDermott
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsAlexandra Bailey, David F McDermott
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell CarcinomaXin Gao, David F McDermott
Nature Reviews. Rheumatology|December 24, 2014
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuumSinisa Savic, Michael F McDermott
Current Opinion in Molecular Therapeutics|December 15, 2010
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular diseaseJanina Geiler, Michael F McDermott
Pageof 67

Showing results (41-50 of 666) with videos related to

Sort By:
Pageof 67
BMJ (Clinical Research Ed.)|October 1, 1994
Protection afforded by cycle helmetsF McDermott, J Lane
Virchows Archiv. B, Cell Pathology|August 25, 1978
Epithelial cell population kinetics of isolated ileal loops (thirty-vella fistulae) after 40% small in testinal resection. Autoradiographic studies in the ratF McDermott, B Roudnew
The Medical Journal of Australia|December 30, 1978
Compulsory blood alcohol testing of road crash casualties in Victoria: the first three yearsF McDermott, P Strang
Current Opinion in Rheumatology|December 2, 2016
Lessons from characterization and treatment of the autoinflammatory syndromesIvona Aksentijevich, Michael F McDermott
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2003
BMS-561392. Bristol-Myers SquibbMartin Grootveld, Michael F McDermott
Plos Medicine|September 1, 2006
A proposed classification of the immunological diseasesDennis McGonagle, Michael F McDermott
Cancer Journal (Sudbury, Mass.)|July 23, 2013
Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeuticsAlexandra Bailey, David F McDermott
Cancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell CarcinomaXin Gao, David F McDermott
Nature Reviews. Rheumatology|December 24, 2014
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuumSinisa Savic, Michael F McDermott
Current Opinion in Molecular Therapeutics|December 15, 2010
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular diseaseJanina Geiler, Michael F McDermott
Pageof 67